For GA, secondary to AMD
Coverage policies are subject to change and vary from plan to plan.
Navigating the prior authorization (PA) process
Some health plans may require a PA describing your patient’s medical history and the reasons why you feel SYFOVRE is the right medication for your patient. Other plans may require a precertification for the CPT code based on site of care. It is important to check with your patient’s health plan to ensure you are using the correct form and supplying all of the required information. To avoid delays, it is recommended to consider including a Letter of Medical Necessity to support the PA submission.
Refer to the checklist and resources below for guidance on fulfilling PA requirements. Or contact your Apellis Field Reimbursement Manager (FRM) or call ApellisAssist at 888-APELLIS (888-273-5547) for information on PA requirements.
PA checklist
Helpful reminders for the PA process
Refer to the Access & Reimbursement Guide
for more information
Letter of Medical Necessity
(some payers may require this)
Refer to the Sample Letter of Medical Necessity
for examples of the types of information you may want to include
What happens next?
Refer to the Sample Letter of Appeals for examples of the types of information you may want to include
AMD=age-related macular degeneration; GA=geographic atrophy.
Reference: 1. Data on file. Apellis Pharmaceuticals, Inc; 2024.
SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).